President and Chief Operating Officer of Acelyrin, Inc.
Robert F. Carey has served as a member of Sangamo’s Board of Directors since June 2016. Mr. Carey currently serves as President and Chief Operating Officer of Acelyrin, Inc., a biopharmaceutical company focused on identifying, acquiring, and accelerating development and commercialization of promising drug candidates. Prior to Acelyrin, Mr. Carey served as executive vice president, chief business officer for Horizon Pharma plc from March 2014 to October 2019, and served as managing director and head of the healthcare investment banking group at JMP Securities LLC, a full-service investment bank, from March 2003 to March 2014. Previously, Mr. Carey was a managing director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities International, Inc., and held roles at Shearson Lehman Hutton and Ernst & Whinney. Mr. Carey also serves on the board of directors of Beyond Air, Inc. Mr. Carey received his B.S. in accounting from the University of Notre Dame.
Kenneth Hillan, M.B. Ch.B.
Sandy Macrae, M.B., Ch.B., Ph.D.
John Markels, PH.D.
James R. Meyers
President and Chief Executive Officer of IntraBio
James R. Meyers has served as a member of Sangamo’s Board of Directors since November 2019 and has over 30 years of commercial leadership experience in the biotechnology industry. Mr. Myers serves as President and Chief Executive Officer at IntraBio, a biopharmaceutical company focused on novel therapies for neurodegenerative diseases. Prior to IntraBio, Mr. Meyers served as Gilead’s Executive Vice President of Worldwide Commercial Operations, where he was responsible for global commercial activities, including pricing and market access in North America, Europe, Middle East, Australia and Japan. At Gilead, he successfully led several important product launches in the HIV and hepatitis C therapeutic areas. Prior to Gilead, Mr. Meyers held positions of increasing responsibility with Zeneca Pharmaceuticals and Astra USA. He currently serves on the Board of Directors of two public companies, Arbutus Biopharma Corp. and CytomX Therapeutics, and he remains an active advisor to several major biopharmaceutical companies. Mr. Meyers holds a B.S. in Economics from Boston College.
H. Stewart Parker
Saira Ramasastry has served as a member of Sangamo’s Board of Directors since June 2012. Ms. Ramasastry has served as Managing Partner of Life Sciences Advisory, LLC, a company that she founded to provide strategic advice, business development solutions and innovative financing strategies for the life science industry since April 2009. Ms. Ramasastry also serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research, and as business and sustainability lead for the European Prevention of Alzheimer’s Dementia consortium. She is currently a member of the board of directors for VIR Biotechnology, Glenmark Pharmaceuticals, and Akous. Ms. Ramasastry was an investment banker with Merrill Lynch & Co., Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, strategic and capital markets transactions from August 1999 to March 2009. Prior to joining Merrill Lynch she served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998.
Ms. Ramasastry received her B.A. in economics with honors and distinction and an M.S. in management science and engineering from Stanford University, as well as an M. Phil. in management studies from the University of Cambridge where she is a guest lecturer for the Bioscience Enterprise Programme. Ms. Ramasastry is also a Health Innovator Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network.